NEW YORK, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Section 232 investigations target pharmaceutical ingredients and chips, with public comment open for 21 days starting Wednesday. Trump plans to announce semiconductor tariff rates soon, while offering ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...

Global drugmakers’ stocks dropped across the board today after U.S. President Donald Trump reiterated plans for a “major” tariff on pharmaceutical imports, threatening an interwoven supply ...

HERZLIYA, Israel and CALGARY, AB, April 7, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a ...

Following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD, Innocan is actively advancing its efforts to strengthen ...

RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on April 3 and set a price target of $330.00. The company’s shares closed yesterday at $235.74.

Yunnan Baiyao Group Co. Ltd. A 0.26% ¥101.44B Tasly Pharmaceutical Group Co. Ltd. A 0.84% ¥23.13B Jiangsu Hengrui Medicine Co. Ltd. A 0.37% ¥324.07B Zhejiang Hisun Pharmaceutical Co. Ltd. A 0. ...

Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: "We are very pleased with our outstanding results and especially our strong revenue growth. At BI Sky Global we are clearly ...

COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration ...